Exogenous reinfection with Mycobacterium tuberculosis confirmed by phage typing.
D000636:Aminosalicylic Acids / Q000494:pharmacology; D001434:Bacteriophage Typing; D004352:Drug Resistance, Microbial; D004977:Ethambutol / Q000494:pharmacology / Q000627:therapeutic use; D005000:Ethionamide / Q000494:pharmacology; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009160:Mycobacteriophages; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000201:enzymology / Q000302:isolation & purification*; D012008:Recurrence; D012293:Rifampin / Q000494:pharmacology / Q000627:therapeutic use; D013183:Sputum / Q000382:microbiology*; D013307:Streptomycin / Q000494:pharmacology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000382:microbiology*; D014510:Urease / Q000378:metabolism
D000636:Aminosalicylic Acids; D004977:Ethambutol; D014510:Urease; D005000:Ethionamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin